Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:40:38.100Z.
Calculation as of: 2026-10-06T19:40:38.100Z.
Quote observation: 2026-10-06T19:40:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47b7d046e53ba400f53df530976eb059ace8f079140d97e9bcfa36b682aba175
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$439.31M
EBITDA Yield
N/A
TTM Avg
8.61%
3Y Avg
13.81%
5Y Avg
19.64%
Market Cap
$446.87M
EBITDA Yield
N/A
TTM Avg
702.73%
3Y Avg
702.73%
5Y Avg
702.73%
Market Cap
$449.45M
EBITDA Yield
224.25%
TTM Avg
150.45%
3Y Avg
150.45%
5Y Avg
150.45%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $439.55M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $439.31M | N/A | 8.61% | 13.81% | 19.64% |
| NeuroPace, Inc. (NPCE)vs › | $436.34M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $446.87M | N/A | 702.73% | 702.73% | 702.73% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $449.45M | 224.25% | 150.45% | 150.45% | 150.45% |
| NeoGenomics, Inc. (NEO)vs › | $429.18M | N/A | 1.44% | 5.28% | 7.05% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $425.33M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $454.45M | 4.32% | 6.53% | 7.37% | 6.54% |
| Tilray Brands, Inc. (TLRY)vs › | $423.28M | 4.36% | 3.97% | 3.97% | 3.97% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.04M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
